Meeting
2019 ASCO Annual Meeting
CBT-1 in combination with doxorubicin in patients with metastatic, unresectable sarcomas who previously progressed on doxorubicin.
Authors
Gregory Michael Cote
MGH, Boston, MA
Gregory Michael Cote , Sant P. Chawla , Melissa Amber Burgess , Katherine Anne Thornton , Robert K. Oldham , Scott H. Okuno , Karla V. Ballman , Susan Matlow , Daryl Barnett , Steven Attia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03002805
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS11077)
DOI
10.1200/JCO.2019.37.15_suppl.TPS11077
Abstract #
TPS11077
Poster Bd #
398b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).
First Author: Eoghan Ruadh Malone
Poster
2023 ASCO Annual Meeting
Phase 1 trial of avelumab with hypofractionated thoracic radiation therapy (HT-RT) in patients with metastatic soft-tissue sarcomas (mSTS).
First Author: Shane H Zaidi
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Casper: A phase I, open-label, dose finding study of calaspargase pegol-mnkl (cala) in combination with cobimetinib (cobi) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez